Tandem Diabetes Care Stock In Shambles: Down -25% With 7-Day Losing Streak
Tandem Diabetes Care (TNDM) – a provider of insulin delivery systems and diabetes management software – hit a 7-day losing streak, with cumulative losses over this period amounting to -25%. The company’s market cap has crashed by about $427 Mil over the last 7 days and currently stands at $1.3 Bil.
Is this an opportunity or a trap? There are a few things to fear in TNDM stock, given its overall Weak operating performance and financial condition. This is aligned with the stock’s Low valuation, because of which we think it is Fairly Priced (For details, see Buy or Sell TNDM).
But here is the interesting part. You are reading about this -25% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- Exxon Mobil Stock On A Winning Streak: Time To Get In Or Book Profits?
- Is Ralph Lauren Stock Optimizing Returns Through the Denominator Effect?
- Is Qualcomm Stock A Cheap Cash Machine With Big AI Potential?
- Microsoft Stock’s Path To $450
- Delta Premium Gains Squeezed by Fuel Shock
- Four Risks To Watch For Palantir Stock In The Next 6 Months
The following table summarizes the return for TNDM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TNDM | S&P 500 |
|---|---|---|
| 1D | -1.9% | 0.7% |
| 7D (Current Streak) | -25.0% | -0.1% |
| 1M (21D) | -20.8% | -3.5% |
| 3M (63D) | -16.4% | -4.7% |
| YTD 2026 | -14.4% | -3.9% |
| 2025 | -39.0% | 16.4% |
| 2024 | 21.8% | 23.3% |
| 2023 | -34.2% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: TNDM Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 127 S&P constituents with 3 days or more of consecutive gains and 24 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 108 | 17 |
| 4D | 6 | 5 |
| 5D | 5 | 2 |
| 6D | 0 | 0 |
| 7D or more | 8 | 0 |
| Total >=3 D | 127 | 24 |
Key Financials for Tandem Diabetes Care (TNDM)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $940.2 Mil | $1.0 Bil |
| Operating Income | $-99.1 Mil | $-167.3 Mil |
| Net Income | $-96.0 Mil | $-204.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $249.3 Mil | $290.4 Mil |
| Operating Income | $-22.9 Mil | $8.3 Mil |
| Net Income | $-21.2 Mil | $-0.6 Mil |
The losing streak TNDM stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.